Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
Abstract Observational studies have suggested that HER2 inhibition with trastuzumab may be associated with an increased incidence of intracranial metastatic disease (IMD) due to its ability to prolong survival. We hypothesized that prolonged survival associated with dual-agent HER2 inhibition may be...
Enregistré dans:
Auteurs principaux: | Anders Wilder Erickson, Steven Habbous, Christianne Hoey, Katarzyna J. Jerzak, Sunit Das |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fbb56a6898a446b5a5e73ebedbd73af9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
par: Laura Pizzuti, et autres
Publié: (2021) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
par: Advani P, et autres
Publié: (2015) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
par: Fara Brasó-Maristany, et autres
Publié: (2020) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
par: Salkeni MA, et autres
Publié: (2021) -
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
par: Abdel Kader Y, et autres
Publié: (2013)